Vivtex's Chief Scientific Officer, Thomas von Erlach, will be presenting at the Boulder Peptide Symposium 2024 on September 19th in Boulder, Colorado, the only conference focused solely on peptide therapeutics. In his presentation, he will discuss the most recent advancement at Vivtex to delivery peptide therapeutics orally using a high throughput formulation screening approach. Join this discussion by registering at https://lnkd.in/gXcki_cA.
Vivtex
Biotechnology Research
Cambridge, Massachusetts 2,678 followers
Pioneering Oral Delivery of Biologics
About us
Vivtex strives to transform drug development using a new platform technology called gastrointestinal tract organ robotic interface system (GI-ORIS™) that enables robotic screening with fully intact and functional organs. GI-ORIS™ technology was developed in the Langer lab at MIT and can be used for various applications (e.g. oral delivery of biologics, drug toxicity mitigation, spatial and temporal drug delivery). Vivtex leverages these unique capabilities of the GI-ORIS™ to develop new oral therapeutics. Vivtex's mission is to serve patients by increasing the efficacy, safety and adherence of existing and novel therapies. The company is in preclinical stage and has multiple drug development programs including reformulations of existing drugs as well as new chemical entities. The company was co-founded by Professor Robert Langer (MIT), Dr. Giovanni Traverso (Harvard Medical School), Doug Eby (Cambridge Science), and Thomas von Erlach.
- Website
-
http://www.vivtex.com
External link for Vivtex
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
- Founded
- 2018
Locations
-
Primary
790 Memorial Dr
Suite 300
Cambridge, Massachusetts 02139, US
Employees at Vivtex
Updates
-
We're excited to introduce Vivtex's new scientific advisors, Tomi Sawyer, Peptide Therapeutics Expert, and Ivor Elrifi, Intellectual Property and Transactions Advisor. Tomi is the Chief Drug Hunter & President of Maestro Therapeutics, a consulting/advisory enterprise supporting peptide drug discovery, which he founded in 2019. Ivor is the Chief Executive Officer of a publicly traded biotech company, and former global chair of Cooley LLP’s patent counseling and prosecution practice. Read more about Tomi and Ivor on our page: https://lnkd.in/e7Cm2TRw
-
Vivtex’s Chief Scientific Officer, Thomas von Erlach, will be discussing formulation optimization through the applications of robotic screening as an expert speaker at the Next Gen Peptide Formulation & Delivery Summit in Boston, MA from June 18-20, 2024. View the full event guide and register at https://lnkd.in/e2bWVv-S.
Next Gen Peptide Formulation & Delivery Summit | Home
next-gen-peptide-formulation.com
-
Vivtex's Chief Executive Officer, Maureen Deehan, will be in San Diego, CA, to attend the BIO International Convention 2024 from June 3rd to June 7th. If you would like to schedule a meeting with her during this time, drop her a message on Linkedin or via the BIO partnering system: https://lnkd.in/ebVNCbJh
-
We’re excited to announce that Vivtex’s Chief Executive Officer, Maureen Deehan, and Chief Scientific Officer, Thomas von Erlach, are featured in the summer issue of the European Biopharmaceutical Review (EBR) discussing the pros and challenges of creating oral biologics. Read the article here: https://lnkd.in/eKpuCvr6
EBR Summer 2024
http://www.calameo.com/
-
Vivtex’s Chief Scientific Officer, Thomas von Erlach will be providing an overview on oral macromolecular drug delivery at the 2024 Global Drug Delivery & Formulation Summit in Berlin. Join us at the conference May 21st - May 23rd. More information at https://lnkd.in/evFJW6G4
-
Congratulations to Vivtex’s CEO, Maureen Deehan, for receiving the Elizabeth Elting Venture Fund Award 2024. The award recognizes highly accomplished women CEO leading the most promising emerging life sciences companies.
-
Vivtex CEO Maureen Deehan, will be attending BIO 2024 in June, in San Diego, CA. If you wish to send Vivtex a meeting request to speak with Maureen, please do so via the BIO partnering system: https://lnkd.in/ebVNCbJh Vivtex looks forward to joining the BIO community from 3rd to 6th June, in San Diego!
BIO One-on-One Partnering
login.partnering.bio.org
-
Vivtex reposted this
We are proud to announce that Vivtex’s Chief Scientific Officer, Thomas von Erlach, will be a featured speaker at the upcoming Peptide Based Therapeutics Summit. Global experts will gather in Boston, MA, from 23rd -25th April to discuss the transformative potential of early phase technology in the development of next-generation peptide-based therapeutics. Here you can find the full event guide and register your place: https://lnkd.in/ebrBuzRy
Full Event Guide - Peptide Based Therapeutics Summit
peptide-based-therapeutics-summit.com
-
We are proud to announce that Vivtex’s Chief Scientific Officer, Thomas von Erlach, will be a featured speaker at the upcoming Peptide Based Therapeutics Summit. Global experts will gather in Boston, MA, from 23rd -25th April to discuss the transformative potential of early phase technology in the development of next-generation peptide-based therapeutics. Here you can find the full event guide and register your place: https://lnkd.in/ebrBuzRy
Full Event Guide - Peptide Based Therapeutics Summit
peptide-based-therapeutics-summit.com